CAJ | 학술논문

目的：探讨索拉非尼联合表阿霉素、氟尿嘧啶治疗原发性肝癌的临床疗效和安全性。方法回顾性分析我院自2003年2月～2010年2月收治的56例原发性肝癌患者，随机分为治疗组及对照组各28例。治疗组：索拉菲尼联合EF方案；对照组单用索拉菲尼，比较两组的总体疗效及不良反应发生率。结果治疗组在有效率、疾病控制率、中位无进展生存时间、中位生存期、1年生存率均优于对照组，差异有统计学意义（P＜0.05）；两组的主要不良反应均为疲乏、高血压、手足皮肤反应、腹泻等，治疗组较对照组除了白细胞减少及恶心、呕吐略差外（P＜0.05），两组间其他不良反应差异无统计学意义（P＞0.05）。结论索拉非尼联合（EF方案）化疗治疗原发性肝癌的近期疗效高，安全性好，患者耐受性好，值得临床进一步研究。
목적：탐토색랍비니연합표아매소、불뇨밀정치료원발성간암적림상료효화안전성。방법회고성분석아원자2003년2월～2010년2월수치적56례원발성간암환자，수궤분위치료조급대조조각28례。치료조：색랍비니연합EF방안；대조조단용색랍비니，비교량조적총체료효급불량반응발생솔。결과치료조재유효솔、질병공제솔、중위무진전생존시간、중위생존기、1년생존솔균우우대조조，차이유통계학의의（P＜0.05）；량조적주요불량반응균위피핍、고혈압、수족피부반응、복사등，치료조교대조조제료백세포감소급악심、구토략차외（P＜0.05），량조간기타불량반응차이무통계학의의（P＞0.05）。결론색랍비니연합（EF방안）화료치료원발성간암적근기료효고，안전성호，환자내수성호，치득림상진일보연구。
Objective To observe the clinical efficacy and safety of sorafenib combined with chemotherapy for hepatocellular carcinoma. Methods 56 patients with Hepatocelular Carcinoma admitted in our hospital from February 2003 to February 20l0,were randomly divided into the treatment group and the control.The treatment group was interfered with sorafenib combined with EF;The control group was treated with sorafenib. Overall efficacy and incidence of adverse reactions were compared. Results The treatment group is more efficacy than the control group in The effective rate (CR+PR),control rate,median follow-up time,median progression-free survival (PFS),median survival (OS)and 1 year survival rate is better in treatment than those in the control,The difference was statistically significant (P<0.05).The major adverse reactions in both groups were fatigue,hypertension,hand-foot skin reaction,diarrhea,etc.In addition,leukopenia,nausea and vomiting were more popular than those in the control(P<0.05),other adverse reactions in both groups were not statistically significant(P > 0.05). Conclusion Sorafenib combined with (EF program) chemotherapy was more efficacy,safety,and well tolerated in the treatment of HepatocelIular Carcinoma.